You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. DEVELOPMENT OF TOPICAL ANTIVIRAL AGENTS FOR TREATING MOLLUSCUM CONTAGIOSUM

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTIONprovided by applicantMolluscum contagiosumMCis a highly contagious skin disease caused by the poxvirusMCVMC appears as lesions on the body and face and can last months years before resolvingLesions occur most frequently in childrenand immune compromised individualsThe infection is confined to skin aloneit is not systemicTransmission spreads directly from person person contactautoinocula ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Tumor Proliferation PET Tracer FLT using a Low Cost Single Dose Automatic Production and Quality Control Biomarker Generator System

    SBC: ABT Molecular Imaging            Topic: 102

    DESCRIPTION provided by applicant Worldwide a person dies from cancer every seconds Positron emission tomography PET is an effective tool that is critical in diagnosing cancer and monitoring treatment efficacy PET imaging relies on use of short lived radioisotopes Commercial distribution of the most commonly used radio tracer F FDG has resulted in patient population coverage in ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Discovery of inhibitors of BK polyomavirus

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    PROJECT SUMMARY Novel inhibitors of BK polyomavirus BKPyV are urgently needed to prevent the occurrence of virus induced nephropathy allograft failure and hemorrhagic cystitis following transplantation The objective of this Phase I SBIR feasibility study is to identify drug like compounds that specifically inhibit BKPyV replication During the course of this Phase I funding period we will exe ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Drug Abuse Policy Surveillance System

    SBC: Legal Science Partners, LLC            Topic: NIDA

    DESCRIPTION provided by applicant Laws regulations and policies play a significant role in prevention and treatment of drug abuse They also have unintended impacts on drug usersandapos behavior and the risk environments they inhabit Scientifically valid legal data is the starting point for the evaluation of the health impact of laws policies and their implementation This project will use ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Epigenetic Probes for HMTs

    SBC: REACTION BIOLOGY CORPORATION            Topic: 100

    DESCRIPTION provided by applicant Epigenetic proteins such as histone methyltransferases represent important potential drug targets for indications like cancers neurodegenerative disorders and cardiovascular and metabolic diseases At Reaction Biology Corporation andquot RBCandquot we are working toward the complete coverage of all epigenetic targets including HMTs to identify and impr ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Exploiting Natural Products-Based Therapeutics for Aflatoxin Mitigation

    SBC: CFD RESEARCH CORPORATION            Topic: CBD152003

    Aflatoxins are a paradigm among fungal produced mycotoxins that are present in food supplies and are strongly associated with increased risk forthe development of hepatocellular carcinoma. Currently, there are no known countermeasures that can selectively mitigate aflatoxin toxicity andthe available options are only symptomatic treatments. To meet this challenge, we propose to harness the microbio ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  7. Functional Assessment using a Virtual Environment

    SBC: Psychology Software Tools, Inc.            Topic: N

    This Phase II project will develop a computer based tool for the functional assessment of higher level instrumental activities of daily living IADLs using simulated activities in a virtual environment VE IADLs are the high level activities such as managing finances and complex medication regimens and successfully negotiating novel or new situations that are necessary for fully independent liv ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia

    SBC: DISCOVERYBIOMED, INC.            Topic: 200

    DESCRIPTION provided by applicant DiscoveryBioMed Inc DBM Inc or DBM specializes in normal and diseased human cell platform engineering DBM has assembled a consortium of experts whereby collectively we seek Fast Track SBIR funding to establish and offer a Product Line Menu of normal and ADPKD human cell platforms for the academic and industry marketplaces Existing and interested DBM ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Glycosaminoglycan Interacting Small Molecule GISMO as Parkinson s Therapeutic

    SBC: GISMO THERAPEUTICS INC.            Topic: 106

    Glycosaminoglycan Interacting Small Molecule GISMO As Parkinsonandapos s Therapeutics ABSTRACT Current approved drugs for Parkinsonandapos s Disease PD treat the symptoms of the disease but do not stop disease progression This project is focused on developing a new disease modifying PD therapeutic with a novel mode of action that is expected to block disease progression Recent data indicate ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers

    SBC: Atrin Pharmaceuticals            Topic: 103

    PROJECT SUMMARY Specific targeting of the Ataxia Telangiectasia and Rad related kinase ATR represents an emerging strategy to treat a broad spectrum of cancers most notably those that currently lack effective treatments Suppression of ATR selectively kills cells subjected to oncogenic stress alternative lengthening of telomeres ALT or loss of double strand break DSB repair mechanisms A ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government